Johnson & Johnson's decision to launch a mid-stage study evaluating a slate of hepatitis C drugs that includes Achillion Pharmaceuticals' ACH-3102 could lead to a best-in-class hepatitis C therapy down the road.
In the following slideshow, I outline what you need to know about this trial and why it matters to Achillion Pharmaceuticals' investors.
Continue Reading Below
The article Why Achillion Pharmaceuticals Shares Soared in October originally appeared on Fool.com.
Todd Campbell owns shares of ACHILLION PHARMACEUTICALS, INC. and Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.